In light of the recent MSKCC Phase 2 data indicating reduced skeletal events with treatment, how will you approach management of patients with asymptomatic bone mets?   

How will you approach patients with diffuse metastases who you would have otherwise deferred treatment?

Prophylactic Radiation Therapy vs. Standard-of-Care for Patients with High-Risk, Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Trial.

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution
Radiation Oncologist at Stroger Hospital
Full manuscript would be highly informative.
Sign in or Register to read more